Rethinking psychedelic-assisted therapy in eating disorders
Psychedelic-assisted therapy in eating disorders is gaining momentum as researchers search for innovative treatments. Early studies suggest that psychedelics like psilocybin may help people with conditions such as anorexia or binge eating disorder. However, many trials risk overlooking a key factor: the deeply personal and subjective nature of the psychedelic experience itself.
Traditional study designs often reduce outcomes to numbers and checklists, which may not capture the richness of how people experience these therapies. This gap between lived experience and clinical data could mean missing crucial insights about why psychedelic-assisted therapy works—or why it sometimes doesn’t.
Why phenomenology matters
Phenomenology, the study of lived experience, offers tools to explore the subtle aspects of psychedelic journeys. Instead of focusing only on symptoms, it investigates how people experience their bodies, emotions, time, relationships, and sense of self.
In eating disorders, these domains—embodiment, intersubjectivity, affectivity, temporality, spatiality, and selfhood—are central to both the illness and the potential healing process. By applying phenomenology, researchers can better understand how psychedelic experiences influence these dimensions and how that relates to recovery.
Moving beyond standard measures
Current research often uses broad psychological scales that may not capture fleeting, pre-verbal, or deeply personal aspects of the psychedelic state. For example, a patient’s shift in how they relate to their body may not be reflected in a symptom checklist but could be pivotal to recovery.
Microphenomenology, which examines short-lived and subtle experiences, could complement standard methods. This approach allows researchers to gather detailed accounts of how psychedelic sessions unfold, leading to more precise hypotheses and outcome measures.
Building better future studies
Integrating phenomenology into study design does not replace traditional methods—it enriches them. Qualitative interviews, experiential mapping, and patient-centered measures could sit alongside symptom scales and brain imaging, offering a fuller picture of psychedelic-assisted therapy in eating disorders.
By bridging the gap between experience and science, researchers may uncover why some individuals benefit greatly from psychedelics while others do not. This knowledge could ultimately shape more effective and personalized treatments.
Conclusion
Psychedelic-assisted therapy in eating disorders holds great promise, but to realize its full potential, research must go beyond surface-level outcomes. A phenomenological perspective can provide a richer understanding of how these therapies impact patients’ lived experiences and guide future clinical practice.
Citations:
- Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective. View the full commentary on the Journal of Eating Disorders website:
https://jeatdisord.biomedcentral.com/articles/10.1186/s40337-025-01394-9 BioMed Central - Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Access the original study published in Nature Medicine (July 24, 2023):
https://www.nature.com/articles/s41591-023-02455-9 Nature